SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 9.8% Stake in Akero Therapeutics
Beneficial Ownership Report
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have filed an amended Schedule 13G, reporting a beneficial ownership of 9.8% in Akero Therapeutics, Inc. as of December 31, 2024.
Summary
- RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Akero Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 6,859,823 shares of Akero Therapeutics, Inc. Common Stock.
- This represents 9.8% of the outstanding Common Stock, calculated based on 69,799,148 shares outstanding as of October 31, 2024, as reported by the Company in its Form 10-Q.
- Both RTW Investments, LP and Roderick Wong, M.D. hold shared voting power and shared dispositive power over all 6,859,823 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Akero Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain subjective information to assess sentiment beyond a neutral reporting of a significant stake.
Future Outlook
NA
Industry Context
This Schedule 13G filing is a standard regulatory disclosure by an investment firm, RTW Investments, LP, and its managing partner, Roderick Wong, M.D., regarding their significant passive ownership stake in Akero Therapeutics, Inc., a biotechnology company. Such filings provide transparency on large institutional holdings but do not typically offer insights into the issuer's operational performance or broader industry trends beyond the fact of investment.
Stakeholder Impact
- Shareholders: Provides transparency on a significant institutional holding, potentially signaling confidence from a specialized investment firm in the biotechnology sector.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date as of which 69,799,148 shares of Akero Therapeutics, Inc. Common Stock were reported outstanding in the Company's Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement, representing the beneficial ownership reporting period end. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 2 was signed and filed by RTW Investments, LP and Roderick Wong, M.D. |
Keywords
Akero Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.